PTX 2.56% 3.8¢ prescient therapeutics limited

Ann: December 2018 Appendix 4C - Quarterly, page-2

  1. 1,656 Posts.
    lightbulb Created with Sketch. 198
    Good quarterly update.
    The science model progressing nicely.
    Imminent commencement of the Ptx-100 trial (s), awaiting collaboration results/finding and current concurrent three trials of the Ptx-200 as scheduled.
    The business model on funding is nearing review (IMO).
    That is, current funds at 4.2 mil (including tax rebate), yet next quarter estimated at a burn rate of 2.2mil.
    Obviously a plausible explanation as to the recent sell down we are/ have witnessed.
    So, interesting two quarters re CR requirements...
    , let’s hope timing, past mistakes, dilution and holder  value ( not just majors) are on the boards and ceo’s Priorities.
    GLTAH
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.8¢
Change
-0.001(2.56%)
Mkt cap ! $30.60M
Open High Low Value Volume
3.9¢ 3.9¢ 3.8¢ $47.91K 1.256M

Buyers (Bids)

No. Vol. Price($)
11 881755 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 150000 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.